Evaluating the impact of treatments and clinical factors on thyroid cancer outcomes
Official title: Retrospective and Prospective Evaluation of the Impact of Innovative and Conventional Treatments and of Clinical Variables on the Outcome of Thyroid Cancer
Run by Istituto Auxologico Italiano · NCT05752604 · Data updated 2026-11-12
This study looks at how different treatments and health factors affect the outcomes for people with thyroid cancer to help identify which patients might need less aggressive treatment.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 3000 (estimated) |
| Sponsor | Istituto Auxologico Italiano Academic / other |
| Locations | 1 site (Milan) |
| Status | Recruiting |
| Started | July 12, 2022 |
| Main results expected | March 8, 2032 |
| Study ends | March 8, 2042 |
| Registry record updated | August 3, 2025 |
| Trial ID | NCT05752604 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are individuals diagnosed with thyroid cancer who can provide informed consent.
✕Probably not a fit
Patients who are unable to sign informed consent will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study focuses on patients diagnosed with thyroid cancer to assess how various clinical and histopathological factors influence their prognosis. By analyzing anamnestic data and treatment interventions, the study aims to differentiate between aggressive and indolent tumor behaviors, potentially reducing unnecessary treatments. The outcomes will include morbidity, mortality, and the effectiveness of therapeutic choices, along with any adverse events associated with treatments.
Why it matters
Potential benefit: If successful, this study could lead to more personalized treatment approaches for thyroid cancer patients, improving outcomes and reducing overtreatment.
How similar studies have gone: While this approach is observational and builds on existing knowledge, similar studies have shown promise in improving treatment strategies for cancer patients.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: \- thyroid cancer diagnosis Exclusion Criteria: * patients unable to sign informed consent
Where it's running
-
Istituto Auxologico Italiano, IRCCS
Milan, Italy Recruiting
Study contacts
- Study coordinator: Laura Fugazzola, MD
- Email: l.fugazzola@auxologico.it
- Phone: +390261911
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
MRG003 added to ongoing treatment after progression in EGFR-positive advanced thyroid cancer
In this study, researchers test whether adding MRG003 to a patient’s current thyroid cancer treatment can shrink tumors for those whose cancer initially responded but later progressed.
-
Selective coverage radiotherapy vs. full coverage radiotherapy for poorly differentiated and anaplastic thyroid cancer
This trial tests whether covering only the tumor-affected area with radiation is as effective as full-area coverage radiotherapy for poorly differentiated and anaplastic thyroid cancer, while aiming to reduce side effects and improve quality of life.
-
Trop-2 Targeted PET/CT for Recurrent and Metastatic Thyroid Cancer
This study tests whether a Trop-2 targeted PET/CT scan can better detect recurrent or metastatic thyroid cancer in adults than another PET/CT scan (FAPI).
-
WeChat-supported neck exercises after thyroidectomy
A telehealth program using a WeChat mini program tests if guided neck exercises after thyroid surgery help early recovery and quality of life.
-
Pralsetinib Drug Interaction Study in RET Fusion/MUTATION Positive Solid Tumors
This trial tests whether pralsetinib changes how the body processes certain medicines in adults with RET fusion- or mutation-positive advanced solid tumors.
-
AI chatbot to guide thyroid cancer patients through perioperative education
A new AI chatbot is being tested to see if it helps thyroid cancer patients better prepare for discharge, recover well, and stay engaged in their care compared with traditional education.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.